Finerenone was recently approved by the US Food and Drug Administration for treatment of diabetic kidney disease (DKD). However, the commentary from Sridhar et al1 on the FIDELIO trial2 minimizes hyperkalemia and overstates the superiority of finerenone over other mineralocorticoid receptor antagonists (MRAs). The authors state that few patients discontinued finerenone owing to hyperkalemia (2.3% vs 0.9%). However, the enrollment criteria were crafted to minimize this, requiring a potassium level